These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 30730278)

  • 1. Hyperprogressive disease in hepatocellular carcinoma with immune checkpoint inhibitor use: a case series.
    Wong DJ; Lee J; Choo SP; Thng CH; Hennedige T
    Immunotherapy; 2019 Feb; 11(3):167-175. PubMed ID: 30730278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma.
    Kim CG; Kim C; Yoon SE; Kim KH; Choi SJ; Kang B; Kim HR; Park SH; Shin EC; Kim YY; Kim DJ; Chung HC; Chon HJ; Choi HJ; Lim HY
    J Hepatol; 2021 Feb; 74(2):350-359. PubMed ID: 32810553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature.
    Feng D; Guan Y; Liu M; He S; Zhao W; Yin B; Liang J; Li Y; Wang J
    Front Immunol; 2021; 12():608292. PubMed ID: 34135884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice.
    Yumita S; Ogasawara S; Nakagawa M; Maruta S; Okubo T; Itokawa N; Iino Y; Obu M; Haga Y; Seki A; Kogure T; Ishino T; Ogawa K; Fujiwara K; Iwanaga T; Fujita N; Sakuma T; Kojima R; Kanzaki H; Koroki K; Inoue M; Kobayashi K; Kiyono S; Nakamura M; Kanogawa N; Saito T; Kondo T; Nakagawa R; Nakamoto S; Muroyama R; Chiba T; Itobayashi E; Atsukawa M; Koma Y; Azemoto R; Ito K; Mizumoto H; Kato J; Kato N
    BMC Gastroenterol; 2023 Mar; 23(1):101. PubMed ID: 37003980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperprogression after first dose of immunotherapy in a patient with radioresistant metastasis from nonsmall cell lung cancer.
    Bosch-Barrera J; Oliva E; Sais E; Vásquez CA; Roselló A; Menéndez JA
    Anticancer Drugs; 2019 Nov; 30(10):1067-1070. PubMed ID: 31567311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria.
    Matos I; Martin-Liberal J; García-Ruiz A; Hierro C; Ochoa de Olza M; Viaplana C; Azaro A; Vieito M; Braña I; Mur G; Ros J; Mateos J; Villacampa G; Berché R; Oliveira M; Alsina M; Elez E; Oaknin A; Muñoz-Couselo E; Carles J; Felip E; Rodón J; Tabernero J; Dienstmann R; Perez-Lopez R; Garralda E
    Clin Cancer Res; 2020 Apr; 26(8):1846-1855. PubMed ID: 31757877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Advances in Hyperprogressive Disease in Patients 
with Advanced Non-small Cell Lung Cancer Treated with Immunotherapy].
    Yao S; Shi K; Zhang Y
    Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):271-278. PubMed ID: 33910275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-1
    Kamada T; Togashi Y; Tay C; Ha D; Sasaki A; Nakamura Y; Sato E; Fukuoka S; Tada Y; Tanaka A; Morikawa H; Kawazoe A; Kinoshita T; Shitara K; Sakaguchi S; Nishikawa H
    Proc Natl Acad Sci U S A; 2019 May; 116(20):9999-10008. PubMed ID: 31028147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities.
    Kanjanapan Y; Day D; Wang L; Al-Sawaihey H; Abbas E; Namini A; Siu LL; Hansen A; Razak AA; Spreafico A; Leighl N; Joshua AM; Butler MO; Hogg D; Chappell MA; Soultani L; Chow K; Boujos S; Bedard PL
    Cancer; 2019 Apr; 125(8):1341-1349. PubMed ID: 30768786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperprogressive disease in advanced cancer patients treated with nivolumab: a case series study.
    Petrioli R; Mazzei MA; Giorgi S; Cesqui E; Gentili F; Francini G; Volterrani L; Francini E
    Anticancer Drugs; 2020 Feb; 31(2):190-195. PubMed ID: 31850916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors.
    Shen P; Han L; Ba X; Qin K; Tu S
    Front Pharmacol; 2021; 12():678409. PubMed ID: 34290608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperprogressive Disease in Malignant Carcinoma With Immune Checkpoint Inhibitor Use: A Review.
    Liu X; Qiao L
    Front Nutr; 2022; 9():810472. PubMed ID: 35399666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel immunotherapeutic approaches for hepatocellular carcinoma treatment.
    Busato D; Mossenta M; Baboci L; Di Cintio F; Toffoli G; Dal Bo M
    Expert Rev Clin Pharmacol; 2019 May; 12(5):453-470. PubMed ID: 30907177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18-12.
    Park JH; Chun SH; Lee YG; Chang H; Lee KW; Kim HR; Shin SH; An HJ; Lee KE; Hwang IG; Ahn MJ; Kim SB; Keam B
    J Cancer Res Clin Oncol; 2020 Dec; 146(12):3359-3369. PubMed ID: 32671504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non-small Cell Lung Cancer.
    Lo Russo G; Facchinetti F; Tiseo M; Garassino MC; Ferrara R
    Curr Oncol Rep; 2020 Apr; 22(5):41. PubMed ID: 32296957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperprogressive disease in patients receiving immune checkpoint inhibitors.
    Zhang H; Fang X; Li D; Yang M; Yu L; Ding Y; Shen H; Yuan Y
    Curr Probl Cancer; 2021 Jun; 45(3):100688. PubMed ID: 33334611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma.
    Sangro B; Chan SL; Meyer T; Reig M; El-Khoueiry A; Galle PR
    J Hepatol; 2020 Feb; 72(2):320-341. PubMed ID: 31954495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperprogressive Disease in Lung Cancer with Transformation of Adenocarcinoma to Small-cell Carcinoma during Pembrolizumab Therapy.
    Okeya K; Kawagishi Y; Muranaka E; Izumida T; Tsuji H; Takeda S
    Intern Med; 2019 Nov; 58(22):3295-3298. PubMed ID: 31327828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Immunotherapy in a Tolerogenic Environment: Current and Future Perspectives for Hepatocellular Carcinoma.
    Montella L; Sarno F; Ambrosino A; Facchini S; D'Antò M; Laterza MM; Fasano M; Quarata E; Ranucci RAN; Altucci L; Berretta M; Facchini G
    Cells; 2021 Jul; 10(8):. PubMed ID: 34440678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of the advanced HCC: A second revolution by using immunotherapy].
    Fartoux L; Rosmorduc O
    Biol Aujourdhui; 2018; 212(3-4):85-87. PubMed ID: 30973137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.